On January 10, Jackson sold 12,041 shares at a weighted average price of $7.36, with sales prices ranging from $6.99 to $7.95. Additionally, it sold 1,231 shares on the same day at a weighted average price of $8.05, with sales prices ranging between $8.02 and $8.13. Further transactions took place on January 13, when Jackson sold 7,912 shares at an average price of $6.38, with a range of $6.11 to $6.72. Another sale took place on January 14, involving 8,407 shares at an average price of $6.20, with prices ranging from $6.03 to $6.44. These sales totaled $201,133. After these transactions, Jackson holds 112,154 shares of Sera Prognostics, a $216.14M market cap company. For deeper insight into SERA’s insider trading patterns and comprehensive financial analysis, investors can access the detailed Pro Research Report available at InvestingPro.
On January 10, Jackson sold 12,041 shares at a weighted average price of $7.36, with sales prices ranging from $6.99 to $7.95. Additionally, it sold 1,231 shares on the same day at a weighted average price of $8.05, with sales prices ranging between $8.02 and $8.13.
Further transactions took place on January 13, when Jackson sold 7,912 shares at an average price of $6.38, with a range of $6.11 to $6.72. Another sale took place on January 14, involving 8,407 shares at an average price of $6.20, with prices ranging from $6.03 to $6.44.
These sales totaled $201,133. Following these transactions, Jackson holds 112,154 shares of Sera Prognostics.
In other recent news, Sera Prognostics disclosed top-line results from the PRIME study in an abstract published by the Society for Maternal-Fetal Medicine. The study aims to improve neonatal outcomes through preterm birth risk assessment combined with clinical interventions. A more comprehensive presentation of the study results is scheduled for later this month at the SMFM 2025 Pregnancy Meeting.
Sera Prognostics also released its Q3 2024 financials, showing a decrease in net income to $29,000 from $42,000 in Q3 2023. The company’s operating expenses rose 8% to $8.9 million and net loss to 10% to $7.9 million. Despite these numbers, Sera Prognostics maintains a strong cash reserve of $74.3 million, which is projected to sustain operations through 2027.
The company is putting the spotlight on its PreTRM test, with the goal of improving its application in the fight against the rising rate of premature births in the US. CEO Evguenia Lindgardt emphasized the importance of the imminent publication of the PRIME clinical study results, which are expected to play a key role in securing payer support and influencing clinical guidelines. These recent developments highlight Sera Prognostics’ strategy for commercial growth and maintaining solid cash reserves in the coming years.
This article was generated with the support of artificial intelligence and reviewed by an editor. See our T&C for more information.
